Menu
Search
|

Menu

Close
X

Aeglea Bio Therapeutics Inc AGLE.OQ (NASDAQ Stock Exchange Global Market)

6.35 USD
-0.01 (-0.16%)
As of Feb 23
chart
Previous Close 6.36
Open 6.40
Volume 12,700
3m Avg Volume 14,856
Today’s High 6.40
Today’s Low 6.02
52 Week High 8.14
52 Week Low 2.81
Shares Outstanding (mil) 16.64
Market Capitalization (mil) 104.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
5
FY15
6
EPS (USD)
FY17
-1.417
FY16
-1.737
FY15
-1.008
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
21.07
8.35
Price to Book (MRQ)
vs sector
1.87
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
0.00
15.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-42.37
13.63
Return on Equity (TTM)
vs sector
-42.42
15.39

EXECUTIVE LEADERSHIP

Armen Shanafelt
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Anthony Quinn
Interim Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
George Georgiou
Co-Founder, Director, Since
Salary: --
Bonus: --
Charles York
Chief Financial Officer, Vice President, Since 2015
Salary: --
Bonus: --
Henry Hebel
Vice President - Product Development, Since 2015
Salary: $144,000.00
Bonus: $28,800.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

901 S. Mopac Expressway
Ste. 250, Barton Oaks Plaza One
AUSTIN   TX   78746

Phone: +1512.9422935

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

SPONSORED STORIES